Genentech is investing $750 million in a new drug delivery device facility at its Hillsboro, Oregon site, with the project expected to come online as operations expand for device-enabled therapies. The update is positioned around advanced manufacturing capacity for components that integrate with drug delivery. The facility investment adds to the recurring theme in biotech manufacturing: scaling device and combination-product infrastructure alongside biologics and other therapeutics. For device delivery modalities, dedicated capacity can shorten lead times and support more consistent supply. While the article focuses on the capital commitment and timing, it also signals Genentech’s continued emphasis on platform-like manufacturing capabilities rather than relying solely on external partners. Program teams evaluating device-centric assets are likely to take cues from this spend as a proxy for how large sponsors plan capacity allocations for combination and delivery technologies.